Back to Search
Start Over
Correlations between plasma endothelin-1 levels and breakthrough pain in patients with cancer.
- Source :
-
OncoTargets & Therapy . Dec2015, Vol. 8, p3703-3706. 4p. 2 Charts. - Publication Year :
- 2015
-
Abstract
- Abstract: Endothelin-1 (ET-1) may be involved in driving pain in patients with advanced cancer. However, a few studies focus on the role of ET-1 in breakthrough pain (BP). The aim of this pivotal study was to explore the correlation between the plasma (ET-1) level and BP intensity. A total of 40 patients were enrolled in the study, and they were divided into two groups: BP group and non-BP group. Moreover, 20 healthy adults were used as the normal control group. Pain intensity was measured using visual analog scale (VAS) scores of 1–10. Plasma ET-1 levels were detected by an ET radioimmunoassay kit. Subsequently, the correlation of ET-1 level with the VAS score and cancer types was analyzed by Pearson’s correlation coefficient. The plasma ET-1 level in the BP group (35.31±8.02 pg/mL) was higher than that in the non-BP group (29.51±6.78 pg/mL) and the normal control group (24.77±10.10 pg/mL, P,0.05). In addition, the VAS score in the BP group (7.45±0.82) was higher than that in the non-BP group (2.80±1.23, P,0.05). The plasma ET-1 level was positively correlated with the VAS score of the BP group (Pearson’s r=0.42). There was no significant correlation between the plasma ET-1 level and VAS score of the non-BP group (Pearson’s r=−0.22) or/and cancer types (P.0.05). The elevated plasma ET-1 levels were positively related to BP, and targeting ET-1 may provide a novel pain-reducing therapeutic treatment in BP. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 11786930
- Volume :
- 8
- Database :
- Academic Search Index
- Journal :
- OncoTargets & Therapy
- Publication Type :
- Academic Journal
- Accession number :
- 112158017
- Full Text :
- https://doi.org/10.2147/OTT.S90272